Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback